M3541

CAS No. 1360628-91-6

M3541( —— )

Catalog No. M36357 CAS No. 1360628-91-6

M3541 is a selectively potent and orally active ATM inhibitor with potential antitumor activity.M-3541 inhibits ATM kinase activity and ATM-mediated signaling by binding to ATM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 787 Get Quote
5MG 1112 Get Quote
25MG 1766 Get Quote
50MG 2190 Get Quote
100MG 2790 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    M3541
  • Note
    Research use only, not for human use.
  • Brief Description
    M3541 is a selectively potent and orally active ATM inhibitor with potential antitumor activity.M-3541 inhibits ATM kinase activity and ATM-mediated signaling by binding to ATM.
  • Description
    DNA-PK-IN-11 is a DNA-PK inhibitor with an IC50 of <0.1 μM (DE102010035744A1; compound 36).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis | ATM/ATR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1360628-91-6
  • Formula Weight
    428.42
  • Molecular Formula
    C23H17FN6O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 5 mg/mL (11.67 mM; Ultrasonic (<60°C)
  • SMILES
    O=C1N(C=2C=3C(=CC(OC)=C(C3)C4=CN(C)N=C4)N=CC2N1C)C5=C(F)C=C(C#N)C=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Dr. Fuchss Thomas, et al. Imidazolonylchinoline. DE102010035744A1.
molnova catalog
related products
  • Rigosertib

    Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM).

  • D609

    D609 (Tricyclodecan-9-yl-Xanthogenate) has a wide range of biological activities including antioxidant, antiapoptotic, anticholinergic, antitumor, anti-inflammatory, antiviral, antiproliferative, and neuroprotective activities.

  • LYG-202

    LYG-202 is a novel flavonoid with piperazine substitution and antitumor effects in vivo and in vitro.LYG-202 induced apoptosis in MCF-7, MDA-MB-231, and MDA-MB-435 cells, and increased intracellular ROS production.